RM-END / Endocrine and peptide-hormone analogs
Ovagen
Also known as: EDL peptide (market usage) · Glu-Asp-Leu (market usage)
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Ovagen is a market name, not a sufficiently complete chemical identity. Public pages variously describe liver, ovarian or broader tissue positioning and do not agree on the sequence.
Evidence position
Grade U is intentional. The library will not transfer evidence from EDL, EDE or a tissue extract to an Ovagen-labelled material until the exact sequence and analytical record are supplied.
What the record does not establish
A PubChem entry for one proposed sequence and a supplier label do not establish what is in a vial. No clinical outcome, safety record or lot verification is implied.
Sources
- 01Ovagen evidence reviewOpen Assay
- Shows
- Documents current EDL market usage, zero assay samples and the absence of an exact PubMed-indexed Ovagen record
- Does not show
- Editorial secondary index; Open Assay states its own testing program is still being established
- 02EDL chemical identityPubChem
- Shows
- Registry identity for glutamyl-aspartyl-leucine
- Does not show
- Does not establish that every product called Ovagen is EDL
- 03Conflicting Ovagen sequence assignmentASCEND
- Shows
- A current secondary page assigns EDE rather than EDL, documenting a live market conflict
- Does not show
- Secondary content, included only to show naming inconsistency; not evidence for either identity
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Glutamyl-aspartyl-leucine
- CID
- 444128
- Formula
- C15H25N3O8
- Mass
- 375.37